2.1
Brentuximab vedotin (Adcetris, Takeda) is indicated for 'adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD)'.
2 Information about brentuximab vedotin
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for brentuximab vedotin.
Price
2.3
The list price of brentuximab vedotin is £2,500 per 50‑mg vial (excluding VAT; BNF online, accessed November 2024).
2.4
The company has a commercial arrangement. This makes brentuximab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence.